Repigmentation of Vitiligo with Topical Tacrolimus

Smith, D. A.; Tofte, Susan J.; Hanifin, Jon M.

doi:10.1159/000065845

Cited by 49 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Smith et al [24] and Travis et al [25] have reported cases of successful treatment of vitiligo with 0.1% tacrolimus ointment. Prospective patient series of Grimes et al [26] and Tanghetti [27] have also shown the effectiveness of tacrolimus ointment 0.1% in the treatment of vitiligo.…”

Section: Discussionmentioning

confidence: 99%

Pimecrolimus Cream in Repigmentation of Vitiligo

Hassan

Farnaghi

Firooz³

et al. 2007

Dermatology

View full text Add to dashboard Cite

Background: Vitiligo is a chronic disease that mostly affects children and young adults. Nowadays many treatment options are available; however, most of them have limited efficacy and in most cases would result in undesirable complications. Objective: To determine the extent of repigmentation according to the location of the lesions after applying topical cream pimecrolimus 1% in vitiligo patients. Materials and Methods: Thirty consecutive patients with vitiligo lesions affecting less than 20% of body surface area without any previous history of spontaneous repigmentation were treated with pimecrolimus cream 1% twice daily for 12 weeks. The extent of repigmentation in vitiligo lesions was determined in each patient after 6 and 12 weeks. Results: Moderate to excellent response (repigmentation >26%) was observed in 6.6 and 25.9% of vitiligo lesions 6 and 12 weeks after treatment, respectively. More responsive lesions were located on the trunk, face and elbow (85.7, 75 and 70%). Conclusion: Pimecrolimus cream 1% results in repigmentation in vitiligo in different extents according to the location of the lesion; however, to clearly prove its efficacy as monotherapy or in combination with other available treatment options, double-blind placebo-controlled studies are essential.

show abstract

Section: Discussionmentioning

confidence: 99%

Pimecrolimus Cream in Repigmentation of Vitiligo

Hassan

Farnaghi

Firooz³

et al. 2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…Improvement of quality of life is related to a patient’s satisfaction with care, and both may have a positive effect on treatment adherence and/or outcome [9,10,11]. Various available treatment options aim to inhibit further progress of the disease and/or induce repigmentation [12,13,14]. Few studies have assessed the effect of treatment on the quality of life [15].…”

Section: Introductionmentioning

confidence: 99%

Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage

Ongenae¹,

Dierckxsens²,

Brochez³

et al. 2005

Dermatology

158

154

View full text Add to dashboard Cite

Background: Few studies have paid attention to the effects of treatment interventions on the psychosocial consequences of vitiligo. Objectives: To quantify and analyse the psychosocial benefit of the use of camouflage in vitiligo patients. Patients and Methods: 78 vitiligo patients completed the Dermatology Life Quality Index (DLQI) and an adapted stigmatization questionnaire, and 62 of them completed the DLQI after at least a 1-month use of camouflage. Results: The initial mean overall DLQI score (n = 78) is 6.9 (SD 5.6). The mean global stigmatization score is 38%. Disease extent and disease severity are strong predictors of the DLQI (p < 0.0001). Vitiligo on the face/head/neck substantially affects the DLQI, independently of degree of involvement. The mean DLQI score before and after use of camouflage (n = 62) is 7.3 (SD 5.6) and 5.9 (SD 5.2; p = 0.006). Mainly the high-scoring items ‘feelings of embarrassment and self consciousness’ and ‘choice of clothing’ improve. Predictors of improvement are higher DLQI scores (p = 0.0005) and higher total severity scores (p = 0.03). Conclusions: Camouflage can be recommended, particularly in patients with higher DLQI scores or self-assessed disease severity. Patients with minor involvement of the face benefit from camouflage.

show abstract

“…Both Grimes et al [2] and Smith et al [3] have demonstrated the effectiveness of tacrolimus, a topical immunomodulatory agent, in the treatment of vitiligo in both children and adults. Based on this report, we decided to use the newer topical immune modulator, pimecrolimus, for the treatment of vitiligo.…”

Section: Introductionmentioning

confidence: 99%